Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
Arch Orthop Trauma Surg ; 142(5): 805-811, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-33459821

RESUMEN

INTRODUCTION: In low-income countries (LIC), international surgeons face the fact that there are patients they cannot treat. The goal of this study was to identify and analyze patients lost to treatment. MATERIAL AND METHODS: We analyzed retrospectively the data of 282 trauma victims from a non-governmental organizational (NGO) hospital in Sierra Leone, Africa. During a 3-month period (10.10.2015-08.01.2016), these patients had 367 injuries and underwent 263 orthopedic surgeries. Despite a clear indication, some patients did not receive surgical treatment. We identified these injuries and the reason why they could not be operated. The anatomic region of the injury was evaluated and if they had a bone or soft tissue defect or were infected. RESULTS: We identified 95 (25.89%) injuries in 70 patients (47 males; 23 females) that were not be operated. The reasons were lack of specific implants (no implant group; N = 33), no treatment strategy for the injury (no solution group; N = 29), and patients that were lost (lost patient group; N = 33), almost equally distributed by 1/3. In the no implant group were mainly closed fractures and fractures of the pelvis and the proximal femur. The implants needed were locking plates (N = 19), proximal femoral nails (N = 8), and implants for pelvic surgery (N = 6). In the no solution group were nearly all bone (P < 0.0000), soft tissue defects (P < 0.00001) and infections (P = 0.00003) compared to the rest and more open fractures (P < 0.00001). In the lost patients group, most fractures were closed (24 out of 33, P = 0.033). These fractures were mostly not urgent and were postponed repeatedly. CONCLUSION: One quarter of the patients did not receive the surgical treatment needed. Besides acquisition of implants, surgical skills and expertise could be a solution for this issue. Nevertheless, these skills must be passed to local surgeons.


Asunto(s)
Fracturas Abiertas , Triaje , Femenino , Hospitales , Humanos , Masculino , Estudios Retrospectivos , Sierra Leona
2.
Int Orthop ; 46(1): 21-27, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-33638004

RESUMEN

PURPOSE: Lack of resources, severe injuries, and logistical flaws force surgeons in low-income countries (LIC) to improvise during surgery and use implants "off-label." These off-label treatments are specific for the work of trauma surgeons in non-governmental (NGO) hospitals in LIC. The aim of this study is to show the need of off-label surgery in an environment of low resources by means of typical examples. METHODS: Off-label treated fractures, the implant used instead, and the reason for off-label treatment were investigated in 367 injuries over a three month period in an NGO hospital in Sierra Leone. RESULTS: Twenty-seven fractures were treated off-label with mostly K-wires (88.89%) and external fixators (51.85%). Three reasons for off-label use could be defined: no suitable implants (N = 14), the condition of soft tissues that did not allow internal osteosyntheses (N = 10), and implants not ready for surgery due to logistic flaws (N = 3). The implants needed were mostly locking plates. CONCLUSION: Surgeons in similar settings must use K-wires and external fixators to treat complex fractures. Using implants off-label can help surgeons to treat fractures otherwise left untreated.


Asunto(s)
Placas Óseas , Uso Fuera de lo Indicado , Hilos Ortopédicos , Fijadores Externos , Fijación Interna de Fracturas , Humanos
3.
Int Orthop ; 44(12): 2521-2527, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32915284

RESUMEN

PURPOSE: The aim of the study was to identify solution strategies from a non-governmental (NGO) hospital in a war region for violence-related injuries and to show how high-income countries (HIC) might benefit from this expertise. METHODS: NGO trauma hospital in Lashkar Gah, Afghanistan. Four hundred eighty-four war victims admitted in a three month period (February 2016-May 2016) were included. Patients´ characteristics were analyzed. RESULTS: The mean age was 23.5 years. Four hundred thirty-four (89.9%) were male, and 50 (10.1%) were female. The most common cause of injury was bullet injuries, shell injuries, and mine injuries. The most common injured body region was the lower extremity, upper extremity, and the chest or the face. Apart from surgical wound care and debridements, which were performed on every wound in the operation theatre, laparotomy was the most common surgical procedure, followed by installation of a chest drainage and amputation. CONCLUSION: The surgical expertise and clear pathways outweigh modern infrastructure. In case of a mass casualty incident, fast decision-making with basic diagnostic means in order to take rapid measurements for life-saving therapies could make the difference.


Asunto(s)
Amputación Quirúrgica , Laparotomía , Adulto , Afganistán/epidemiología , Causalidad , Femenino , Humanos , Masculino , Estudios Retrospectivos , Adulto Joven
4.
Minerva Urol Nefrol ; 59(4): 455-8, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17947963

RESUMEN

Myelolipoma of the adrenal gland is a benign, endocrinologically inactive neoplasm composed of mature adipose tissue and a variable amount of hematopoietic elements. Rarely giant adrenal myelolipomas have been reported in literature and they are very unusual clinical entities. We describe a case in a 72 year-old woman observed at our Department of Urology for nausea, flank and abdominal pain. The surgical resected mass measured 16.5x11.5x10 cm and weighted 1 250 g. A survey of the literature on this topic is made.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Mielolipoma , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Neoplasias de las Glándulas Suprarrenales/cirugía , Adrenalectomía , Anciano , Femenino , Humanos , Mielolipoma/diagnóstico , Mielolipoma/cirugía , Resultado del Tratamiento
6.
Anticancer Res ; 25(5): 3597-9, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16101186

RESUMEN

Recent experimental observations, showing the potential role of prolactin (PRL) as a tumor growth factor for prostate cancer and the unfavourable prognostic significance of enhanced chromogranin-A-secreting neuroendocrine cell proliferation, could contribute to a better understanding of the mechanisms responsible for the occurrence of hormone-resistance in the prostate cancer. Moreover, it has been shown that tamoxifen, which consistently exerts estrogenic activity in males, may inhibit prostate cancer cell proliferation in experimental studies. At present, there are no clinical data in humans. This preliminary phase II study was planned in an attempt to evaluate the therapeutic efficacy of tamoxifen in hormone-refractory metastatic prostate cancer. The study included 14 consecutive metastatic prostate cancer patients, who had progressed under the classical endocrine therapy with LHRH-analogs and/or anti-androgens. Patients received the same treatment plus tamoxifen at 20 mg/day orally. A decline greater than 50% in prostate-specific antigen (PSA) levels occurred in 4/14 (29%) patients within the first 2 months of therapy, with a median duration of 5 months. Mean pre-treatment levels of PRL were significantly higher in responder patients than in those who progressed. Moreover, abnormally high pre-treatment levels of PRL were found in 5/14 (36%) patients. The percent of clinical responses observed in patients with pre-treatment hyperprolactinemia was significantly higher than that found in patients with normal pre-treatment PRL concentrations. Finally, a significant decline in mean PRL levels upon tamoxifen therapy occurred only in the responder patients. This preliminary study seems to justify further clinical research to confirm the potential efficacy of tamoxifen in the treatment of hormone-refractory prostate cancer and to identify possible parameters, which may predict the response to treatment.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Prolactina/metabolismo , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/metabolismo , Tamoxifeno/uso terapéutico , Anciano , Anciano de 80 o más Años , Antagonistas de Andrógenos/uso terapéutico , Resistencia a Antineoplásicos , Hormona Liberadora de Gonadotropina/análogos & derivados , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias Hormono-Dependientes/metabolismo
7.
Int J Biol Markers ; 20(2): 123-5, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16011043

RESUMEN

The hormone resistance of prostate cancer has been proved to depend at least in part on enhanced neuroendocrine activity and the resultant increase in blood concentrations of chromogranin A. Other experimental observations have suggested the involvement of prolactin (PRL), which appears to be a potential growth factor for prostate cancer. Abnormally high levels of PRL have been detected in metastatic prostate cancer, but the clinical significance of this finding has still to be clarified. In an attempt to explain the prognostic significance of serum PRL levels in prostate cancer, in this preliminary study we have analyzed the PRL levels in a group of metastatic prostate cancer patients with hormone-dependent or hormone-resistant cancer. The study included 50 patients with metastatic prostate cancer, 15 of whom had hormone-resistant tumors. The serum levels of PRL were measured by the RIA method. Abnormally high concentrations of PRL were found in 11/50 (22%) patients. Moreover, the percent of patients with cancer-related hyperprolactinemia was significantly higher in the hormone-resistant group than in the hormone-dependent group (8/15 vs 3/35, p < 0.01). This study confirms the possible existence of a hyperprolactinemic state in metastatic prostate cancer, as previously reported by other authors. Moreover, it appears to demonstrate that the occurrence of hyperprolactinemia is more frequent in hormone-resistant neoplasms, suggesting the possible involvement of PRL in hormone independence. Further studies concomitantly evaluating PRL and chromogranin A blood concentrations will be necessary to establish whether the hyperprolactinemia precedes and promotes the onset of hormone resistance in prostate cancer, or whether it is simply a consequence of the hormone independence.


Asunto(s)
Prolactina/sangre , Neoplasias de la Próstata/sangre , Anciano , Cromogranina A , Cromograninas/sangre , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Neoplasias Hormono-Dependientes/sangre , Neoplasias de la Próstata/terapia
8.
Int J Biol Markers ; 20(2): 123-125, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-28207138

RESUMEN

The hormone resistance of prostate cancer has been proved to depend at least in part on enhanced neuroendocrine activity and the resultant increase in blood concentrations of chromogranin A. Other experimental observations have suggested the involvement of prolactin (PRL), which appears to be a potential growth factor for prostate cancer. Abnormally high levels of PRL have been detected in metastatic prostate cancer, but the clinical significance of this finding has still to be clarified. In an attempt to explain the prognostic significance of serum PRL levels in prostate cancer, in this preliminary study we have analyzed the PRL levels in a group of metastatic prostate cancer patients with hormone-dependent or hormone-resistant cancer. The study included 50 patients with metastatic prostate cancer, 15 of whom had hormone-resistant tumors. The serum levels of PRL were measured by the RIA method. Abnormally high concentrations of PRL were found in 11/50 (22%) patients. Moreover, the percent of patients with cancer-related hyperprolactinemia was significantly higher in the hormone-resistant group than in the hormone-dependent group (8/15 vs 3/35, p<0.01). This study confirms the possible existence of a hyperprolactinemic state in metastatic prostate cancer, as previously reported by other authors. Moreover, it appears to demonstrate that the occurrence of hyperprolactinemia is more frequent in hormone-resistant neoplasms, suggesting the possible involvement of PRL in hormone independence. Further studies concomitantly evaluating PRL and chromogranin A blood concentrations will be necessary to establish whether the hyperprolactinemia precedes and promotes the onset of hormone resistance in prostate cancer, or whether it is simply a consequence of the hormone independence. (Int J Biol Markers 2005; 20: 123-5).

9.
Arch Ital Urol Androl ; 73(3): 140-2, 2001 Sep.
Artículo en Italiano | MEDLINE | ID: mdl-11822056

RESUMEN

Radical prostatectomy today has become a frequent operation in all urology wards. An increasing attention is nowadays paid to the question of post-operation continence, which is considered a fundamental aspect for a good quality of life. The Authors propose two variations to the Walsh's technique: conservation of the distal sphincter obtained by "digitoclasic" isolation of the same and conservation of the proximal sphincter obtained by means of a personal preparation technique of the vesical neck and anastomosis of the same to the urethral stump. The record of cases, not large enough, and in particular some initial failures occurred during the finalization phase of the technique, do not yet allow to draw final conclusions.


Asunto(s)
Prostatectomía/métodos , Incontinencia Urinaria/prevención & control , Anciano , Humanos , Masculino , Persona de Mediana Edad , Prostatectomía/efectos adversos , Incontinencia Urinaria/etiología
10.
Arch Ital Urol Androl ; 68(5): 293-8, 1996 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-9026229

RESUMEN

PURPOSE: evaluation of results and complications of ileal orthotopic neobladders in men and women with transitional cell carcinoma. MATERIALS AND METHODS: between 12-89 and 12-95 we performed 146 radical cystectomy for bladder neoplasm, in 32 patients we can perform ileal orthotopic neobladder, 29 were male and 3 were female. Oncologic indications to this kind of operation were: clinical stage T2, T3a, T3b, T1G3 multicentric and or recurrence, absence of metastasis absence of nodal metastasis, negativity of urethral biopsy. General contraindications were urethral stenosis and incontinence. Oncological contraindications, in woman, were bladder neck neoplasm or urethral neoplasm. In 4 patients we use Camey II technique, in 19 pts we performed the paduan ileal neobladder, in 9 pts we use Hautmann technique. 7 patients performed neoadjuvant chemotherapy with 4 circles of MVAC, 4 pts underwent adjuvant chemotherapy, and 2 pts salvage chemotherapy. In woman we take care during cystectomy to dissect cardinal ligament very close to cervix uteri, to resect the uterosacral ligament far to the sacrum. We did not dissect under the ureter and we cut the urethra 0.5-1 cm far from the bladder neck. RESULTS: follow up was between 6 and 66 months. 24 patients are now alive and disease free, 2 patients are alive with disease progression, 1 have a pelvic recurrence and 1 have pulmonary recurrence. 4 pts died for disease progression and 2 for non oncological cause, quality of life was considered as regard to continence and sexual activity. 1 pts was completely incontinent and 1 pts has nocturnal incontinence with a daily micturation every 1 hour. We can evaluate only 18 patients for sexual activity and 4 reported normal erection. COMPLICATIONS: in three cases we had to reoperate for early complications due to mechanical bowel obstruction, ileocutaneous fistula and wound dehiscence. In three cases we had the formation of stones, in two patients ureteroileal stenosis, in two cases urethro-ileal stenosis and 1 reflux from the neobladder. Orthotopic ileal neobladder allows a very good quality of life and is the first choice derivation after radical cystectomy.


Asunto(s)
Carcinoma de Células Transicionales/cirugía , Neoplasias de la Vejiga Urinaria/cirugía , Derivación Urinaria/métodos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Transicionales/tratamiento farmacológico , Quimioterapia Adyuvante , Cisplatino/uso terapéutico , Terapia Combinada , Contraindicaciones , Cistectomía , Doxorrubicina/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Masculino , Metotrexato/uso terapéutico , Complicaciones Posoperatorias , Factores Sexuales , Factores de Tiempo , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Vinblastina/uso terapéutico
11.
Arch Ital Urol Androl ; 67(2): 149-53, 1995 Apr.
Artículo en Italiano | MEDLINE | ID: mdl-7787857

RESUMEN

The intravenous immunotherapy with high-dose interleukin-2 (IL-2) would constitute one of the most effective treatments of metastatic renal cell carcinoma (RCC). More recently, IL-2 subcutaneous therapy has also appeared active, either alone or in association with interferon, with results comparable to those found with the intravenous route of injection, but with a lower toxicity. On this basis, we have designed a protocol of treatment with low-dose IL-2 alone given subcutaneously as a first or a second line therapy in metastatic RCC. The study included 60 consecutive patients (pts) (M/F: 39/21, median age 56 years, range 26/74). IL-2 was given at a dose of 3 millions IU twice/day for 5 days/week, for 6 weeks, corresponding to one cycle. In non progressed pts a second cycle was repeated after a 28-day rest period. Dominant metastasis sites were, as follows: soft tissues: 8; bone: 11; lung: 29; liver: 3; liver plus lung: 7; adrenal: 2. The minimum follow-up was 18 months and the median follow-up was 34 months (range 18-48). A complete response (CR) was achieved in 2/60 (3%) pts. A partial response (PR) was obtained in 15/60 (25%). Therefore, tumor objective rate (CR + PR) was 17/60 (28%). The median duration of response was 13 months (4-33).(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Carcinoma de Células Renales/terapia , Inmunoterapia , Interleucina-2/administración & dosificación , Neoplasias Renales/terapia , Adulto , Anciano , Carcinoma de Células Renales/secundario , Femenino , Estudios de Seguimiento , Humanos , Inyecciones Subcutáneas , Neoplasias Renales/patología , Masculino , Persona de Mediana Edad , Proyectos Piloto , Pronóstico , Inducción de Remisión
12.
Arch Ital Urol Androl ; 67(2): 143-7, 1995 Apr.
Artículo en Italiano | MEDLINE | ID: mdl-7787856

RESUMEN

AIMS AND BACKGROUND: the antitumor activity of IL-2 is mediated by an increase in lymphocyte number. Moreover, our previous studies have shown that therapy for 1 week/month with low-dose subcutaneous IL-2 is sufficient to maintain high levels of lymphocytes in cancer patients who have had tumor regression or stable disease (SD) in response to IL-2 immunotherapeutic cycles. This study was performed to establish whether tumor progression in cancer patients chronically treated with IL-2 may be associated with lymphocyte number decline. METHODS: the study included 60 metastatic renal cell patients, who were treated with 2 induction cycles of IL-2 subcutaneous immunotherapy (6 million IU/day for 5 days/week for 6 weeks, corresponding to one cycle). Tumor regression occurred in 17/60 patients, 23 patients a SD, and the remaining 20 cases progressed. Non-progressed patients (n = 40) underwent a maintenance therapy consisting of one week of therapy every month. After a median follow-up of 18 months, 29/40 patients with response or SD had progressed. The immune investigation consisted of lymphocyte, T lymphocytes, NK cell number determination and sCD25 level detection. RESULTS: the mean number of lymphocytes, T lymphocytes and NK cells observed on IL-2 maintenance therapy was significantly higher than that seen before beginning the immunotherapy. Moreover, mean number of lymphocytes and mean levels of sCD25 observed at the time of tumor progression were respectively lower and higher than those seen on maintenance therapy in the same patients, without, however, significant differences. CONCLUSION: despite the importance of lymphocytes in mediating the antitumor activity of IL-2, this study shows that tumor progression in cancer patients chronically treated with low-dose IL-2 after response or SD during IL-2 induction cycles is not associated with a significant decline in lymphocyte, T lymphocyte or NK cell numbers. Further studies, carried out to analyze the functional status of immune cells at the time of tumor progression, will be necessary to define the role of immunity in cancer patients progressing under IL-2 chronic therapy.


Asunto(s)
Carcinoma de Células Renales/tratamiento farmacológico , Interleucina-2/administración & dosificación , Neoplasias Renales/tratamiento farmacológico , Linfocitos/efectos de los fármacos , Carcinoma de Células Renales/sangre , Carcinoma de Células Renales/secundario , Femenino , Estudios de Seguimiento , Humanos , Inyecciones Subcutáneas , Neoplasias Renales/sangre , Neoplasias Renales/patología , Recuento de Linfocitos/efectos de los fármacos , Masculino , Persona de Mediana Edad , Inducción de Remisión
13.
Pharmacol Res ; 29(3): 281-9, 1994 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8058599

RESUMEN

The distribution of the oxidation polymorphism related to cytochrome CYP2D6 (debrisoquine type) was determined in 246 healthy Italian volunteers. Phenotyping was based on HPLC determination of the dextrometorphan/dextrorphan concentration ratio (metabolic ratio) in urine samples collected over an 8 h interval following a single oral 30 mg dose of dextromethorphan hydrobromide. Urinary excretion of dextromethorphan showed a wide interindividual variability, ranging from < or = 0.04 to 3.9% and from 0.5 to 79.6% of the dose, respectively. Metabolic ratios ranged from < or = 0.001 to 6.6. Eleven of the 246 subjects showed a metabolic ratio greater than 0.30, indicating that 4.5% of the population could be ascribed to the poor metabolizer status. The frequency of the poor metabolizer phenotype in this population is within the range described for other Caucasian ethnic groups.


Asunto(s)
Sistema Enzimático del Citocromo P-450/genética , Oxigenasas de Función Mixta/genética , Citocromo P-450 CYP2D6 , Dextrometorfano/orina , Dextrorfano/orina , Femenino , Humanos , Italia , Hígado/química , Masculino , Fenotipo , Polimorfismo Genético/genética , Grupos Raciales
14.
Arch Ital Urol Androl ; 66(1): 5-10, 1994 Feb.
Artículo en Italiano | MEDLINE | ID: mdl-8012425

RESUMEN

The technique for radical cystoprostatectomy was modified to avoid injury to the branches of pelvic plexus that innervate the corpora cavernosa (monolateral neurovascular bundle preservation or "Nerve sparing technique"). The studies of Walsh and coll. demonstrated that the branches of pelvic plexus that innervate the corpora cavernosa are situated between the rectum and urethra and penetrate the urogenital diaphragm near to the muscular wall of the urethra. Injuries to the pelvic plexus can occur during 1) division of posterior pedicle of bladder (the seminal vesicle can be used as a landmark intraoperatively to avoid injury to pelvic plexus), 2) during apical dissection of prostate with transection of the urethra. The return of sexual function postoperatively is related to preservation of autonomic innervation; the excision of the neurovascular bundle on one side may prevent impotence in 68% patients. Our study was undertaken to identify the cause of impotence in men undergoing radical cystoprostatectomy with "Nerve sparing technique" using bulbo cavernous reflex. Our results suggest that bulbo cavernosus reflex may not be a sensitive clinical tool to establish a diagnosis of neurogenic erectile dysfunction after pelvic surgery. The Authors examine the recent neuro-uro-physiological diagnostic methods for the study of neurogenic erectile dysfunction.


Asunto(s)
Cistectomía/efectos adversos , Disfunción Eréctil/etiología , Plexo Hipogástrico/lesiones , Pene/inervación , Prostatectomía/efectos adversos , Reflejo Anormal , Vesículas Seminales/cirugía , Anciano , Disfunción Eréctil/diagnóstico , Disfunción Eréctil/prevención & control , Humanos , Plexo Hipogástrico/fisiopatología , Escisión del Ganglio Linfático/efectos adversos , Masculino , Persona de Mediana Edad , Erección Peniana/fisiología , Complicaciones Posoperatorias/fisiopatología , Neoplasias de la Próstata/cirugía , Uretra/cirugía
15.
Int J Colorectal Dis ; 8(4): 213-6, 1993 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8163896

RESUMEN

Over a period of 14 months between 1990 and 1992, 73 Afghan war wounded with penetrating colon injuries were admitted and treated by a single surgical team in a field hospital of the International Committee of the Red Cross (ICRC). There were 67 males and 6 females, with a mean age of 23 years (range 6 to 80 years). Fifty six (77%) patients had multiple associated injuries; admission was delayed longer than 12 hours in 39 (44%); hypotension or deep shock was present at admission in 34 (47%) and 12 (16%) respectively. At laparotomy faecal contamination was limited to one quadrant in 58 (79.5%) cases and major in 15 (20.5%). Fifty-two (71.2%) patients underwent resection and primary anastomosis and 21 (28.8%) primary repair. Exteriorisation or diverting colostomy were never used. Four (5.5%) patients died and 11 (15%) had postoperative complications. Overall failure rate was 2.7%, including one faecal fistula conservatively treated and one colostomy raised as a precaution in a patient undergoing relaparotomy for intra-abdominal abscess. No primary repair leaked Deaths were significantly related to delay in admission and age, but not to surgical treatment. One stage primary treatment of large bowel injuries from penetrating abdominal wounds has low mortality, failure and colostomy rates suggesting its wider use regardless of risk factors.


Asunto(s)
Traumatismos por Explosión/cirugía , Colon/lesiones , Perforación Intestinal/cirugía , Guerra , Heridas por Arma de Fuego/cirugía , Adulto , Afganistán , Traumatismos por Explosión/etiología , Traumatismos por Explosión/mortalidad , Femenino , Humanos , Perforación Intestinal/etiología , Perforación Intestinal/mortalidad , Masculino , Unidades Móviles de Salud , Cruz Roja , Heridas por Arma de Fuego/etiología , Heridas por Arma de Fuego/mortalidad
16.
Eur J Pharmacol ; 249(3): 307-15, 1993 Nov 16.
Artículo en Inglés | MEDLINE | ID: mdl-7904564

RESUMEN

The alpha 1-adrenoceptor subtypes present in the smooth muscle of urethra and prostate of different animal species, including man, were characterized by using receptor binding techniques. In prostatic urethra and prostate membranes, [3H]prazosin labelled a single population of alpha 1-adrenoceptors (Hill coefficient not different from unity) with a high affinity in the range 0.21-0.51 nM. The number of specific [3H]prazosin binding sites was partially affected by chloroethylclonidine only in human and rat prostate membranes, whereas this agent proved practically devoid of activity in rabbit and dog prostate membranes as well as in the prostatic urethra membranes of all the animal species examined. These findings indicate that in prostatic and urethral membranes the alpha 1-adrenoceptors mainly belong to the alpha 1A subtype. The binding results were confirmed by in vitro functional studies on noradrenaline-induced contractions of rabbit and dog urethral preparations. The agonist-induced contractions were practically unaffected by preincubation of both tissues with chloroethylclonidine, but were sensitive to nifedipine. We found, moreover, a good correlation between the potency of different selective and non-selective alpha 1-adrenoceptor antagonists (WB-4101, 5-methylurapidil, phentolamine, spiperone, prazosin and urapidil) tested against the noradrenaline-induced contractions of rabbit urethra and their affinity for the alpha 1A-adrenoceptor subtype, no correlation with the affinity for the alpha 1B subtype, and a lower correlation with the affinity for the alpha 1C-adrenoceptor subtype.


Asunto(s)
Antagonistas Adrenérgicos alfa/farmacología , Músculo Liso/metabolismo , Próstata/metabolismo , Receptores Adrenérgicos alfa 1/metabolismo , Uretra/metabolismo , Alquilantes/farmacología , Animales , Sitios de Unión , Clonidina/análogos & derivados , Clonidina/farmacología , Perros , Humanos , Masculino , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Norepinefrina/farmacología , Prazosina/metabolismo , Próstata/efectos de los fármacos , Conejos , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 1/fisiología , Especificidad de la Especie , Uretra/efectos de los fármacos
17.
Br J Clin Pharmacol ; 36(4): 366-8, 1993 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12959317

RESUMEN

The kinetics of oxcarbazepine (OXC) and its active metabolite 10-hydroxy-carbazepine (10-OH-CZ) after a single oral OXC dose (600 mg) were compared in healthy control subjects and in epileptic patients treated with phenobarbitone or sodium valproate (n = 8 in each group). In all groups, serum 10-OH-CZ concentrations were much higher than those of the parent drug. In patients on valproate, the kinetics of OXC and 10-OH-CZ did not differ significantly from those observed in controls. In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS). These data indicate that the biotransformation of OXC and 10-OH-CZ may be accelerated by concomitant treatment with phenobarbitone but that the magnitude of this effect is unlikely to be of great clinical significance.


Asunto(s)
Anticonvulsivantes/farmacocinética , Carbamazepina/análogos & derivados , Carbamazepina/farmacocinética , Administración Oral , Adulto , Anticonvulsivantes/sangre , Anticonvulsivantes/uso terapéutico , Carbamazepina/sangre , Interacciones Farmacológicas , Epilepsia/tratamiento farmacológico , Epilepsia/metabolismo , Femenino , Semivida , Humanos , Masculino , Oxcarbazepina , Fenobarbital/uso terapéutico , Ácido Valproico/uso terapéutico
18.
Riv Eur Sci Med Farmacol ; 14(1): 5-8, 1992 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-1529147

RESUMEN

Provided that the surgeon is familiar with small and large bowel surgery, primary resection and anastomosis of the bowel, as well as primary suture of the perforations, are safe and advantageous procedures in treating war related intestinal perforations, whereas the use of colostomosis should be restricted to selected cases.


Asunto(s)
Intestinos/lesiones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Humanos , Intestinos/cirugía , Persona de Mediana Edad , Guerra
19.
Arch Ital Urol Nefrol Androl ; 62(4): 439-42, 1990 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-2150238

RESUMEN

Endoscopic treatment of urethral stenosis is not an alternative to surgical therapy but is an ideal therapeutical partner. The limits of endoscopic resection lie in the lack of anatomopathologican and clinical knowledge regarding the long-term maintenance of stability of the urethral lumen that in every case the internal urethrotomy manages to create. In fact internal urethrotomy is capable of almost totally eliminating the urethral stenosis but with a higher incidence of relapse, even in the short-term. The complications of endoscopic therapy of urethral stenosis are the usual local complications and of mild seriousness. Among the most frequently noted are the swelling and/or peno-scrotal suffusion by incorrect routes, and post-operative urethraemorrhagia. More rarely, but with serious effects, are purulent urethritis or sepsis. In our case list major complications such as priapism, cavernositis or septic shock were not noted. In conclusion endoscopic therapy of urethral stenosis is a simple technique, repeatable with low morbidity and is the best technique in the congenital 'ring'.


Asunto(s)
Endoscopía , Estrechez Uretral/terapia , Endoscopía/efectos adversos , Estudios de Seguimiento , Humanos , Masculino
20.
Minerva Urol Nefrol ; 42(3): 143-5, 1990.
Artículo en Italiano | MEDLINE | ID: mdl-2080439

RESUMEN

Ureterocutaneostomy (UCS) is a urinary diversion (UD) which is current little used, since, in addition to its very invalidating character, especially from a socio-psychological point of view, it is accompanied by complications such as ureteral stenosis, infections and parenchymal injury. Some of these complications may be partly related to the type of prosthesis used. From January 1987 prosthesis in Wiruthan polyurethane, an inert material with excellent biocompatibility features, were used in 20 patients who had to undergo UCS. The use of these long-lasting prosthesis was easy, well tolerated and enabled the patients to achieve a better quality of life. The prosthesis required moderate maintenance and reduced the complications which are often found in UCS. This positive experience prompts the Authors to recommend the use of these prosthesis in patients with UD.


Asunto(s)
Poliuretanos , Prótesis e Implantes , Derivación Urinaria/instrumentación , Anciano , Materiales Biocompatibles , Procedimientos Quirúrgicos Dermatologicos , Estudios de Evaluación como Asunto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA